IGF-1 DES
Preclinical — Animal / cell-model data onlyWhat it is
A truncated, short-acting IGF-1 variant studied for localised growth-factor effects. Potent growth factor.
IGF-1 DES is a truncated, short-acting IGF-1 variant studied for localised growth-factor effects. Same class of risks as LR3 (hypoglycaemia, tissue growth).
Research context
Studied in relation to:
- Localised growth-factor research
Points in its favour in the literature:
- Short, local action
Caveats and unknowns:
- Hypoglycaemia and tissue-growth risks
- No human safety data
- Prohibited in sport
Handling & reference data
Route in published researchSubcutaneous injection is the route most commonly described in the research literature. Often localised.
Reported half-lifevery short (~20–30 min)
Published clinical / research context (not instructions)Reported research ~50–150 mcg, often localised.
Storage (lyophilised)Lyophilised (freeze-dried) powder: refrigerate at 2–8 °C short-term, or freeze at −20 °C or below for long-term storage. Keep sealed and out of light.
Reconstituted solutionOnce reconstituted: keep refrigerated (2–8 °C), protect from light, do not freeze. With bacteriostatic water, commonly used within ~4 weeks; with plain sterile water, within ~24–48 h.
Worked reconstitution example (arithmetic only)e.g. 2 mg vial + 2 mL → 1 mg/mL.
Available research formats
| Strength | SKU |
|---|---|
| 2mg | IGD |
Current pricing (THB with USD/GBP conversion) is shown live in the catalogue, which also has a transparent U-100 reconstitution calculator.